What is the prognosis for a live birth after unexplained recurrent implantation failure following IVF/ICSI?
This study reports a favorable overall prognosis for achieving live birth in women who have previously experienced RIF, especially in those who continue with further IVF/ICSI treatments. However since 51% did not achieve a live birth during the follow-up period, there is a need to distinguish those most likely to benefit from further treatment. In this study, no clinical factors were found to be predictive of those achieving a subsequent live birth.STUDY FUNDING/COMPETING INTEREST(S)This study was funded by the University Medical Center Utrecht, in Utrecht and the Academic Medical Centre, in Amsterdam. NSM has received con...
Source: Human Reproduction - October 17, 2019 Category: Reproduction Medicine Source Type: research
New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
Disclosures: E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, N...
Source: Annals of Allergy, Asthma and Immunology - October 13, 2019 Category: Allergy & Immunology Authors: Yael Renert-Yuval, Emma Guttman-Yassky Tags: Review Source Type: research
LBA63Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
ConclusionsMolecular EC classification has a strong prognostic value in HREC and better identifies those who benefit from adjuvant CTRT than clinicopathological factors. Patients with p53abn HREC had significantly improved RFS with adjuvant CTRT, while those with MMRd did not seem to benefit from chemotherapy. Patients with POLEmut HREC had an excellent RFS in both arms. Future trials should incorporate the molecular classification and target specific subgroups.Clinical trial identificationNCT00411138.Legal entity responsible for the studyLeiden University Medical Center.FundingKoningin Wilhelmina Fonds voor de Nederlandse...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
LBA62Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
ConclusionsThese results suggest clinical benefit from two regimens of Nivo + Ipi in pts with R/M cervical cancer regardless of PD-L1 status. Combo B had notable efficacy in pts with PST. AEs were manageable and consistent with previous reports of Nivo + Ipi therapy.Clinical trial identificationNCT02488759.Editorial acknowledgementWriting and editorial assistance was provided by Brooke Middlebrook of Evidence Scientific Solutions Inc, and funded by Bristol-Myers Squibb.Legal entity responsible for the studyBristol-Myers Squibb, Princeton, NJ, USA.FundingBristol-Myers Squibb, Princeton, NJ, USA.DisclosureR.W. Naumann: Resea...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
454PDFirst in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours
ConclusionsIntravenous administrations of ISU104 were well tolerated up to 20  mg/kg/day without DLT, and showed disease control rate of 60.0%. Safety and efficacy of ISU104 as mono- or combination-therapy and potential biomarkers will be further explored in head and neck, colorectal and breast cancers.Clinical trial identificationNCT03552406.Legal entity responsible for the studyISU Abxis.FundingKDDF: Korea Drug Development Fund.DisclosureB. Keam: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: Genexin; Research grant / Funding (self): ONO; Research grant / Funding (self): MSD; ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
449PDPrecision medicine: Preliminary  results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study
ConclusionsIn patients with metastatic cancer, age< 60 yrs, absence of liver metastases, normal albumin and LDH levels, and absence of KRAS or TP53 mutations were independent factors predicting longer OS. We demonstrated the feasibility of molecular profiling using newly obtained tumor biopsies and treating patients prospectively. The study is ongoing. Outcomes for randomized patients are awaited upon completion of the study.Clinical trial identificationwww.clinicaltrials.gov NCT02152254, First posted June 2, 2014.Legal entity responsible for the studyThe authors.FundingFoundation Medicine.DisclosureA.M. Tsimberidou: Re...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1107TiPA phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma
We present here a trial-in-progress description of this US/EU study, a phase 1 trial with a dose-escalation stage (ESC) and a dose expansion stage (EXP).Trial designStudy Population: The target population is patients (pts) with histologically confirmed R/R NHL, including chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, or Waldenstr öm’s macroglobulinemia/ lymphoplasmacytic lymphoma. In the ESC, patients must have exhausted all available approved therapy options. In the EXP, patients must be naïve to PI3K inhibitors. Objectives: The primary obje...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1106TiPA phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma
We present here a trial-in-progress description of the ongoing US/EU trial, a phase 1 study that includes a dose-escalation and a dose expansion stage.Trial designStudy Population: The target population is adult patients with histologically confirmed relapsed or refractory HL or NHL. To be eligible for enrollment, patients (pts) must have exhausted all approved therapy options available. Objectives: The primary objective is to assess the safety and tolerability of HMPL-523 in pts with relapsed or refractory lymphoma and to determine the maximum-tolerated dose (MTD)/ recommended phase 2 dose (RP2D). Preliminary efficacy in ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
AbstractBackgroundIn BMA117159, GSK2857916, a humanised (IgG1), afucosylated, anti-BCMA monoclonal antibody conjugated to monomethyl auristatin-F, has shown clinical activity (overall response rate [ORR]=60%; mPFS 12 months [95% CI, 3.1 –NE]) as monotherapy in heavily pre-treated patients with MM. Pre-clinical data indicate that GSK’916 induces immunogenic cell death that activates dendritic cells and an antigen-specific T-cell response. PD-L1 overexpression may be a mechanism of immune evasion in MM. Pembrolizumab, a selective , humanised IgG4 anti-PD-1 monoclonal antibody that blocks the interaction of PD-1 with PD-L...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
644PIndependent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
ConclusionsIn patients treated with 5-FU after 2000 the DRP appears to predict benefit. There are no obvious reasons for the lack of prediction before 2000 but options include mRNA degradation, change in handling of samples, or the selection of older patients after 2000. [1] PLOS ONE; 11(5): e0155123.Legal entity responsible for the studyOncology Venture.FundingOncology Venture.DisclosureI.K. Buhl: Full / Part-time employment, Shareholder (immediate family): Oncology Venture. B. Gustavsson: Shareholder / Stockholder / Stock options: Isofol. I.J. Christensen: Advisory / Consultancy, Shareholder / Stockholder / Stock options...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
436TiPA phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: The STELLAR study
AbstractBackgroundGlioblastoma, the most common primary brain tumour in adults, universally recurs with dismal prognosis. To date, clinical trials with protein kinase inhibitors (PKIs) failed to demonstrate efficacy in glioblastoma, possibly due to the blood-brain barrier, which may prevent adequate drug accumulation in the tumour. However, in a pilot study we demonstrated that tumour concentrations of sunitinib, a multi-receptor PKI, in patients with newly-diagnosed glioblastoma are within the range of tumour concentrations measured in metastases from patients with other solid tumours (NCT02239952). In addition, we demons...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
179PDTumor size and overall survival in a cohort of young ( ≤40 years), nodenegative, systemically untreated breast cancer patients; by the PARADIGM study group
ConclusionsT-stage is associated with OS in this patient group. At 20 years follow-up, we found no T-stage with OS rates>90% in N0, systemically untreated patients, meaning that patients regardless of T-stage may benefit from some form of systemic treatment.Legal entity responsible for the studyThe PARADIGM study group.FundingThe Netherlands Organization for Health Research and Development (ZonMW); A Sister ’s Hope; De Vrienden van UMC Utrecht.DisclosureS.C. Linn: Research grant / Funding (self): Amgen; Research grant / Funding (self), unrestricted research grant SUBITO study (NCT02810743): Eurocept-pharmaceuticals; R...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
171TiPPhase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
AbstractBackgroundPoly(ADP-ribose) polymerases (PARPs) play a key role in DNA damage repair (DDR). DDR defects due to HRRm (eg BRCA mutation [BRCAm]) or resulting in HRD (eg global loss of heterozygosity) may sensitize tumors to PARP inhibitors, eg olaparib. Olaparib monotherapy has activity in BRCAm ovarian, breast, pancreatic, and prostate cancer, and in prostate cancer with DDR defects beyond BRCAm (TOPARP). Olaparib improved efficacy outcomes vs placebo/chemotherapy as treatment in  ≤ 3rd-line (3L) HER2-negative BRCAm breast cancer (OlympiAD) and ≥2L BRCAm ovarian cancer (SOLO3), and maintenance therapy in â‰...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
159PPrognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
ConclusionsOur multicentre and multi-assay study suggests that the density of CD8 positive cells in the tumour core is a robust prognostic factor in MIBC. Further investigation of PD-L1 and CD3 cell density is warranted.Legal entity responsible for the studyDefiniens AG; The Walter and Eliza Hall Institute of Medical Research; University of St Andrews.FundingDefiniens AG.DisclosureK. Nekolla: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. N. Brieu: Full / Part-time employment, Definiens is a full subsidiary of AstraZeneca: Definiens AG. C.G. Gavriel: Research grant / Funding (self...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
610PPrognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first-line chemotherapy
ConclusionsThe F/H ratio in patients with mCRC is spread over a wide range of values with the majority below 0.1. High values (>0.34) seem to have prognostic significance and be associated with worse outcome.Legal entity responsible for the studyMedical School, University of Crete.FundingHellenic Oncology Research Group, Medical School, University of Crete.DisclosureZ. Zafeiriou: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Bristol. A. Koutoulaki: F...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
